Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Imunon, Inc. is conducting a Phase I/II clinical trial titled ‘A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.’ The study aims to assess the safety, dosing, efficacy, and biological activity of IMNN-001 when combined with standard chemotherapy in treating advanced ovarian cancer.
The intervention being tested is IMNN-001, a biological treatment formulated with IL-12 plasmid and PEG-PEI-Cholesterol Lipopolymer, designed to enhance the efficacy of chemotherapy in ovarian cancer patients. It is administered intraperitoneally alongside standard chemotherapy drugs, Carboplatin and Paclitaxel.
This randomized, open-label, multicenter trial uses a parallel intervention model with no masking. The primary purpose is to evaluate treatment efficacy, comparing the combination of IMNN-001 with NACT against NACT alone.
The study began on September 5, 2018, and is currently active but not recruiting. The last update was submitted on August 12, 2025, indicating ongoing progress and data collection.
The clinical trial’s progress could impact Imunon’s stock performance, as positive results may boost investor confidence and market valuation. This study positions Imunon in a competitive landscape where advancements in ovarian cancer treatment are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.